PDF(Pubmed)
Abstract：
UNASSIGNED: Kidney damage can result from various factors, leading to structural and functional changes in the kidney. Acute kidney injury (AKI) refers to a sudden decline in kidney function, while chronic kidney disease involves a gradual deterioration lasting more than 3 months. Mechanisms of renal injury include impaired microcirculation, inflammation, and oxidative stress. Cysteinyl-leukotrienes (CysLTs) are inflammatory substances contributing to tissue damage. Montelukast, a leukotriene receptor antagonist, has shown potential renoprotective effects in experimental models of kidney injury.
UNASSIGNED: The authors conducted a scoping review using PubMed, Scopus, and Web of Science databases to identify relevant studies investigating the impact of montelukast on renal diseases. Articles published until 2022 were included and evaluated for quality. Data extraction and analysis were performed based on predetermined inclusion criteria.
UNASSIGNED: The scoping review included 30 studies from 8 countries. Montelukast demonstrated therapeutic effects in various experimental models of nephrotoxicity and AKI induced by agents such as cisplatin, lipopolysaccharide, diclofenac, amikacin, Escherichia coli, cyclosporine, methotrexate, cobalt-60 gamma radiation, doxorubicin, and cadmium. Studies involving human subjects with nephrotic syndrome, pyelonephritis, and other renal diseases also reported positive outcomes with montelukast treatment. Montelukast exhibited anti-inflammatory, anti-apoptotic, antioxidant, and neutrophil-inhibiting properties, leading to improved kidney function and histopathological changes.
UNASSIGNED: Montelukast shows promise as a renoprotective medication, particularly in early-stage kidney injury. Its ability to mitigate inflammation, oxidative stress, and neutrophil infiltration contributes to its therapeutic effects. Further research is needed to explore the clinical applications and mechanisms underlying the renoprotective action of montelukast.
UNASSIGNED: The authors conducted a scoping review using PubMed, Scopus, and Web of Science databases to identify relevant studies investigating the impact of montelukast on renal diseases. Articles published until 2022 were included and evaluated for quality. Data extraction and analysis were performed based on predetermined inclusion criteria.
UNASSIGNED: The scoping review included 30 studies from 8 countries. Montelukast demonstrated therapeutic effects in various experimental models of nephrotoxicity and AKI induced by agents such as cisplatin, lipopolysaccharide, diclofenac, amikacin, Escherichia coli, cyclosporine, methotrexate, cobalt-60 gamma radiation, doxorubicin, and cadmium. Studies involving human subjects with nephrotic syndrome, pyelonephritis, and other renal diseases also reported positive outcomes with montelukast treatment. Montelukast exhibited anti-inflammatory, anti-apoptotic, antioxidant, and neutrophil-inhibiting properties, leading to improved kidney function and histopathological changes.
UNASSIGNED: Montelukast shows promise as a renoprotective medication, particularly in early-stage kidney injury. Its ability to mitigate inflammation, oxidative stress, and neutrophil infiltration contributes to its therapeutic effects. Further research is needed to explore the clinical applications and mechanisms underlying the renoprotective action of montelukast.
摘要：
■肾脏损伤可能是由各种因素引起的，导致肾脏的结构和功能变化。急性肾损伤（AKI）是指肾功能突然下降，而慢性肾脏病则会逐渐恶化，持续超过3个月。肾损伤的机制包括微循环受损，炎症,和氧化应激。半胱氨酰-白三烯(CysLTs)是有助于组织损伤的炎性物质。孟鲁司特,白三烯受体拮抗剂，在肾损伤的实验模型中显示出潜在的肾脏保护作用。
■作者使用PubMed进行了范围审查，Scopus,和WebofScience数据库，以确定调查孟鲁司特对肾脏疾病影响的相关研究。直到2022年发布的文章被纳入其中，并进行质量评估。根据预定的纳入标准进行数据提取和分析。
■范围审查包括来自8个国家的30项研究。孟鲁司特在各种实验模型的肾毒性和AKI诱导的药物如顺铂，脂多糖，双氯芬酸,阿米卡星，大肠杆菌,环孢菌素,甲氨蝶呤,钴-60γ辐射,阿霉素,还有镉.涉及肾病综合征人类受试者的研究，肾盂肾炎,和其他肾脏疾病也报告了孟鲁司特治疗的阳性结果.孟鲁司特表现出抗炎，抗凋亡，抗氧化剂，和嗜中性粒细胞抑制特性，导致改善肾功能和组织病理学变化。
■孟鲁司特显示出作为一种保护肾脏的药物的希望，尤其是早期肾损伤。它减轻炎症的能力，氧化应激，中性粒细胞浸润有助于其治疗效果。需要进一步的研究来探索孟鲁司特的临床应用和肾脏保护作用的潜在机制。
■作者使用PubMed进行了范围审查，Scopus,和WebofScience数据库，以确定调查孟鲁司特对肾脏疾病影响的相关研究。直到2022年发布的文章被纳入其中，并进行质量评估。根据预定的纳入标准进行数据提取和分析。
■范围审查包括来自8个国家的30项研究。孟鲁司特在各种实验模型的肾毒性和AKI诱导的药物如顺铂，脂多糖，双氯芬酸,阿米卡星，大肠杆菌,环孢菌素,甲氨蝶呤,钴-60γ辐射,阿霉素,还有镉.涉及肾病综合征人类受试者的研究，肾盂肾炎,和其他肾脏疾病也报告了孟鲁司特治疗的阳性结果.孟鲁司特表现出抗炎，抗凋亡，抗氧化剂，和嗜中性粒细胞抑制特性，导致改善肾功能和组织病理学变化。
■孟鲁司特显示出作为一种保护肾脏的药物的希望，尤其是早期肾损伤。它减轻炎症的能力，氧化应激，中性粒细胞浸润有助于其治疗效果。需要进一步的研究来探索孟鲁司特的临床应用和肾脏保护作用的潜在机制。
